Project: Targeting the growth hormone receptor for novel and personalized cancer therapeutics
| Acronym | ONCO-TARGET (Reference Number: 115384) |
| Duration | 01/10/2021 - 01/04/2024 |
| Project Topic | We will deliver novel cancer therapeutics that target a unique molecular mechanism - the growth hormone receptor via a novel mode-of-action. Proof-of-concept for preclinical efficacy will be achieved in transgenic models for colorectal cancer (CRC) with a focus on responsive cancer subtype identification and geno-/pheno-typic approaches towards differential sensitivity in vitro and in vivo. The result will be a finalized pre-clinical data package towards CTA enabling and first-in-human studies. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 15 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | IVRS AB | Partner | Sweden |
| 2 | CrownBio | Partner | Netherlands |
| 3 | Specs Compound Handling B.V. | Coordinator | Netherlands |
| 4 | Uppsula University | Partner | Sweden |